Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Ward LM, Högler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Sochett E, Muroya K, Tanaka H, Pitukcheewanont P, Gottesman GS, Biggin A, Perwad F, Chen A, Lawrence Merritt Ii J, Imel EA.
Ward LM, et al. Among authors: imel ea.
JBMR Plus. 2024 Jan 4;8(1):ziad001. doi: 10.1093/jbmrpl/ziad001. eCollection 2024 Jan.
JBMR Plus. 2024.
PMID: 38690124
Free PMC article.
Clinical Trial.